Novo Nordisk Navigates U.S. Weight-Loss Drug Market Challenges

Novo Nordisk faces a challenge in tapping into the U.S. mass market for weight-loss drugs. With new board leadership, the company aims to refocus on consumer channels to regain its market position. The move comes amid increasing competition from U.S. rival Eli Lilly and other cheaper alternatives.

Novo Nordisk, known for its success with obesity drugs, confronts a major hurdle in expanding within the U.S. weight-loss drug market. The company's market position has waned due to competition from Eli Lilly and rising sales of cheaper alternatives.

In response, the Novo Nordisk Foundation, a key investor and non-profit organization, has assumed control of the board, emphasizing a renewed focus on the pivotal U.S. market to drive sales for Wegovy. Former CEO Lars Rebien Sorensen criticized the board's slow adaptation to a dynamic, consumer-oriented obesity market.

Novo is enhancing its consumer strategies, including leveraging online health platforms and exploring insurance coverage options, as it prepares for the launch of a weight-loss pill. Analysts highlight the need for more consumer-centric approaches to meet Wall Street forecasts.